Saxenda (Liraglutide 3 mg) in Children Under 12: What Happens at the Transition to Adult Care

Why Age Matters: Saxenda's Regulatory Boundaries

Saxenda is a once-daily injectable GLP-1 receptor agonist approved at 3.0 mg for chronic weight management. The FDA's approved age range does not extend below 12 years, meaning any use in a child younger than 12 is off-label and lacks efficacy or safety data from a controlled pediatric trial.

Families sometimes ask whether a 10- or 11-year-old with severe obesity could start Saxenda early. The short answer is no, not within approved labeling. The key data supporting the adolescent indication came entirely from patients who were 12 or older.

What the FDA Label Actually Says

The December 2020 label extension granted approval for patients aged 12 to 17 with an initial body weight above 60 kg and a BMI at or above the 95th percentile for age and sex. [1] That 60 kg threshold was set because the pharmacokinetic modeling used for the adult 3 mg dose was only validated at that body weight in adolescents.

Children under 12 were not enrolled in SCALE Teens (NCT02918279), the randomized controlled trial that generated the adolescent data. That trial enrolled 251 participants aged 12 to 17 and ran for 56 weeks. At week 56, the liraglutide group achieved a mean BMI standard deviation score (SDS) reduction of 0.22 versus 0.07 for placebo (P<0.001). [2]

Off-Label Use Risks in Younger Children

Because no controlled data exist for children under 12, prescribing Saxenda in that age group raises unanswered questions about neurodevelopmental effects, bone density during peak accrual years, and the impact of GLP-1-mediated appetite suppression on growth velocity. The Endocrine Society's 2023 obesity pharmacotherapy guidelines state that pharmacological treatment of obesity in children under 12 should remain investigational outside of formal research protocols. [3]

The SCALE Teens Trial: Foundational Data for the Pediatric Label

SCALE Teens (NCT02918279) is the only completed randomized, double-blind, placebo-controlled trial of liraglutide 3 mg in adolescents, and it is the dataset clinicians rely on when managing a patient who will eventually need transition to adult care. [2]

Trial Design and Population

The trial enrolled 251 participants at 37 sites across 13 countries. Participants were 12 to 17 years old, had a BMI at or above the 95th percentile, and weighed more than 60 kg. All participants received diet and exercise counseling. The liraglutide arm received 3.0 mg once daily after a 5-week titration starting at 0.6 mg. The placebo arm followed the same titration shell.

Key Efficacy Outcomes

At 56 weeks, liraglutide 3 mg produced a mean BMI SDS change of -0.22 versus -0.07 for placebo, a statistically significant difference. [2] A clinically meaningful BMI reduction of 5% or more was achieved by 43.3% of liraglutide participants versus 18.7% of placebo participants. Waist circumference, fasting glucose, and triglycerides all showed numerical improvement in the liraglutide group.

The trial did not enroll anyone under 12, and no weight loss outcome data for that age group exist from a controlled Saxenda study.

Safety Signals Relevant to Long-Term Use

Nausea was the most common adverse event, reported by 58% of the liraglutide group versus 18% of placebo. Vomiting occurred in 33% versus 7%. These gastrointestinal rates are higher than those typically seen in the adult SCALE program, which showed nausea in approximately 39% of participants. [4] Clinicians transitioning adolescent patients to adult care should document the GI history in detail, as adult prescribers will use it to calibrate dose management. No thyroid C-cell tumors or cases of pancreatitis were reported in SCALE Teens, consistent with the adult safety database.

Transition to Adult Care: The Clinical Framework

When a patient who has been managed on Saxenda since adolescence turns 18, the transition to adult obesity medicine is not merely an administrative handoff. It requires deliberate planning at least 6 months before the birthday, coordinated record transfer, re-consent under adult standards, and often a formulary or insurance review that may change which agent the patient receives.

Six Months Before the 18th Birthday

At this point, the pediatric or adolescent endocrinologist should complete several tasks. First, a structured treatment summary must be compiled, documenting the starting dose, titration history, adverse events, weight trajectory, and any comorbidities that emerged during treatment. Second, a warm referral to an adult endocrinology or obesity medicine specialist should be placed, not a generic referral letter but a direct conversation or shared EHR handoff.

Third, the clinician should revisit the question of whether liraglutide 3 mg remains the best agent for this now-adult patient. Semaglutide 2.4 mg (Wegovy) received FDA approval for adolescents aged 12 and older in December 2022. [5] The STEP TEENS trial (N=201) showed that semaglutide 2.4 mg produced a mean BMI reduction of 16.1% at 68 weeks versus a 0.6% increase in the placebo group (P<0.001). [6] For a patient switching from Saxenda to Wegovy at the transition point, the substantially larger weight loss effect may justify the change.

The Transition Appointment Itself

The first adult appointment should happen before the 18th birthday if possible, running concurrently with the final pediatric visit. This overlap model, endorsed by the American Academy of Pediatrics for all chronic disease transitions, reduces the probability of treatment gaps. [7]

At the first adult appointment, the clinician should:

• Confirm BMI and weight (adults qualify if BMI ≥30, or ≥27 with a comorbidity such as hypertension, type 2 diabetes, or dyslipidemia)
• Order a fresh metabolic panel, lipid panel, HbA1c, and thyroid-stimulating hormone
• Review the patient's personal and family history for medullary thyroid carcinoma and multiple endocrine neoplasia type 2, given that Saxenda carries a black-box warning for these conditions
• Re-obtain informed consent under adult standards, including discussion of the thyroid tumor risk observed in rodent studies

Insurance and Formulary Realities

Insurance coverage for anti-obesity medications in adults differs substantially from pediatric formularies. The patient may have had Saxenda covered under a pediatric benefit rider that does not carry into adult coverage. Clinicians should initiate prior authorization paperwork at least 60 days before the birthday. If coverage lapses, a bridge supply or patient assistance program enrollment through Novo Nordisk should be arranged to prevent abrupt discontinuation, which carries the risk of weight regain.

Abrupt discontinuation of liraglutide 3 mg is not medically dangerous in the way that abrupt steroid withdrawal is, but weight regain is predictable. The SCALE Maintenance trial showed that participants who discontinued liraglutide 3 mg regained approximately two-thirds of lost weight within 12 weeks of stopping, compared with ongoing weight maintenance in the continuation arm. [8]

Monitoring Parameters at and After Transition

Adult obesity medicine guidelines recommend specific monitoring intervals for patients on GLP-1 receptor agonists. The Obesity Medicine Association and the Endocrine Society both support structured follow-up at 4 weeks, 12 weeks, and every 3 to 6 months thereafter once the patient is stable. [3]

Metabolic Markers to Track

| Parameter | Frequency | Target | |---|---|---| | Body weight and BMI | Every visit | ≥5% reduction from baseline at 12 weeks to confirm response | | HbA1c | Every 6 months | Below 5.7% in non-diabetic patients | | Fasting lipid panel | Annually | LDL <100 mg/dL; triglycerides <150 mg/dL | | Liver enzymes (ALT, AST) | Annually or if symptoms develop | Within normal reference range | | Blood pressure | Every visit | <130/80 mmHg | | Heart rate | Every visit | Liraglutide raises resting heart rate by approximately 2 to 3 bpm; monitor if baseline tachycardia |

Bone Density Considerations

Adolescent obesity is paradoxically associated with lower bone quality despite higher absolute bone mass. [9] Liraglutide's effect on bone mineral density in adolescents has not been rigorously characterized. Patients who spent formative years on a GLP-1 agonist during peak bone accrual (typically ages 12 to 17) may warrant a baseline dual-energy X-ray absorptiometry (DEXA) scan at transition, particularly if there is a history of low vitamin D, low calcium intake, or amenorrhea.

Mental Health Screening

A 2024 FDA review of GLP-1 receptor agonists found no confirmed causal link between these agents and suicidal ideation, though the review noted that the data were insufficient to fully rule out a signal in patients with pre-existing psychiatric conditions. [10] At transition, the adult clinician should screen for depression and anxiety using validated tools (PHQ-9, GAD-7) and document baseline psychiatric status, especially in patients who have experienced weight stigma during adolescence.

When Saxenda Should Not Be Continued After Transition

Not every adolescent patient who was managed on Saxenda should continue that specific agent as an adult. Several clinical scenarios call for a different approach.

Switching to Semaglutide 2.4 mg

A patient who achieved only modest results on liraglutide 3 mg (less than 5% BMI reduction at 6 months) is a reasonable candidate to switch to semaglutide 2.4 mg at transition. The STEP-1 trial (N=1,961) showed that semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% for placebo. [11] The once-weekly dosing schedule may also improve adherence compared with once-daily injection.

Escalation to Tirzepatide

Tirzepatide (Zepbound, 5 mg to 15 mg weekly) received FDA approval for adults with obesity in November 2023. [12] The SURMOUNT-1 trial (N=2,539) showed 20.9% mean weight reduction at the 15 mg dose versus 3.1% for placebo at 72 weeks. [13] Tirzepatide is not yet approved for patients under 18, making the adult transition the first legal opportunity to consider this agent for a patient who needs greater efficacy.

Discontinuation Without Replacement

Some patients or families may prefer to stop pharmacotherapy at transition and attempt lifestyle management alone. This is a valid choice. The clinician's role is to document the expected trajectory: without pharmacotherapy, adults with adolescent-onset obesity have a greater than 80% probability of remaining obese through midlife based on longitudinal cohort data. [14] Setting a clear 3-month checkpoint to reassess is good clinical practice.

Role of the Pediatric Endocrinologist at Handoff

The outgoing pediatric provider carries specific responsibilities that are distinct from the adult team's intake duties.

The American Academy of Pediatrics' "Supporting the Health Care Transition from Adolescence to Adulthood" policy statement specifies that the medical home should prepare a portable medical summary, ensure the young adult has the skills to self-manage the condition, and confirm that insurance coverage is in place. [7] For a patient on Saxenda, self-management skills include the ability to self-inject, recognize and report adverse events, and understand the titration protocol if a dose is interrupted.

Pediatric endocrinologists should also address reproductive health at handoff. Women with obesity who reach reproductive age may have polycystic ovary syndrome or insulin resistance affecting fertility. Liraglutide is Pregnancy Category X-equivalent under current FDA labeling (it is contraindicated in pregnancy based on fetal harm in animal studies). [1] Adult prescribers must ensure the patient understands this and has a contraception plan if sexually active.

Practical Checklist for the Transition Visit

The following checklist applies to any patient who has been on Saxenda since adolescence and is approaching or has reached age 18.

Six months before transition:

• Compile structured treatment summary (start date, doses, weight trajectory, adverse events)
• Place warm referral to adult endocrinology or obesity medicine
• Review current insurance and initiate prior authorization if needed
• Reassess whether liraglutide 3 mg remains optimal versus semaglutide or tirzepatide

At the transition visit:

• Confirm adult-qualifying BMI or BMI plus comorbidity
• Complete full metabolic panel, lipid panel, HbA1c, TSH
• Screen with PHQ-9 and GAD-7
• Re-obtain informed consent including black-box warning discussion
• Discuss contraception for patients of reproductive potential
• Consider baseline DEXA if bone density risk factors are present

Thirty days after transition:

• Confirm prescription fill and insurance coverage
• Assess for injection technique drift (common after provider change)
• Address any new GI symptoms that emerged during transition period

A Note on the Under-12 Population

Children under 12 with severe obesity represent an area of genuine clinical unmet need. No GLP-1 receptor agonist currently carries FDA approval for this age group. Phentermine/topiramate extended-release carries an FDA indication down to age 12. Orlistat is approved to age 12. Below age 12, only intensive lifestyle intervention has regulatory support in the United States. [3]

Research in this area is ongoing. A Phase 3 trial of semaglutide 2.4 mg in children aged 6 to 11 (NCT05605730) is currently enrolling as of early 2025. Results from that trial may eventually shift the lower age boundary for GLP-1 pharmacotherapy, but no data have been published as of this writing. [15]

Clinicians who manage a child under 12 with severe obesity should document the clinical rationale carefully if considering any off-label pharmacological approach, involve a multidisciplinary team, and refer to a pediatric academic center with an established obesity medicine program where possible.